Expanded Access Program for R007 (Probucol) Tablets in Adults With Mitochondrial Disease and Chronic Kidney Disease

Inclusion Criteria A patient must meet all of the following criteria to be eligible: 1. Age 18 to 75 years inclusive; 2. Diagnosis of genetically-confirmed mitochondrial disease with a pathogenic mutation or defect in their mitochondrial or nuclear DNA; 3. Diagnosis of chronic kidney disease stage 3 or stage 4; 4. Moderate or severe symptomatology of mitochondrial disease; 5. A sexually-active patient agrees to practice acceptable methods of contraception throughout the protocol period; 6. The patient is not eligible for, or does not have access to, a clinical trial; 7. The patient (or guardian/legal representative) provides signed and dated informed consent to be treated with probucol in accordance with the expanded access protocol. Exclusion Criteria A patient who meets any of the following criteria will not be eligible: 1. A known hypersensitivity or adverse reaction to probucol; 2. A medical condition or laboratory result that, in the opinion of the treating physician, will interfere with the safe completion of the protocol; 3. An active fungal infection, acute blood, lung, or bladder infection, clinically significant hepatic or renal dysfunction, and/or viral infection (past or present) that, in the opinion of the treating physician, may have a clinically significant effect on their treatment; 4. Taking an investigational drug other than probucol within one month prior to the first dosing with probucol under the protocol; 5. A medical history or condition that increases the potential for QTc prolongation; 6. A female with a positive pregnancy test result or who is breastfeeding; 7. Has received or is receiving kidney dialysis; 8. Has received or is scheduled to receive an organ transplant; 9. Known or suspected active alcohol and/or substance abuse; 10. A history of or current suicidal ideation, behavior, and/or attempts; or 11. Is unable to swallow tablets or requires gastric feeding.